An unmet need in CLL: patients failing ibrutinib and idelalisib

Dr. Zelenetz on Treatment for Patients With CLL Who Fail on Ibrutinib or IdelalisibПодробнее

Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLLПодробнее

CLL: Long-term updates on ibrutinib and idelalisibПодробнее

Options After Second Relapse and Unmet Needs in CLLПодробнее

BCR inhibitors improving CLL patient outcomesПодробнее

Unmet needs in CLL: managing immune complications and patients with high-risk diseaseПодробнее

Dr. Mato on Managing Side Effects With Ibrutinib/Idelalisib in CLLПодробнее

Idelalisib in Chronic Lymphocytic LeukemiaПодробнее

Dr. O'Brien Discusses Ibrutinib and Idelalisib in CLLПодробнее

Dr. Jennifer Brown on Ibrutinib, Idelalisib, and Other Agents for CLLПодробнее

Dr. Kipps on Ibrutinib and Idelalisib For CLLПодробнее

CLL: Addressing Treatment Paradigms and Unmet NeedsПодробнее

Real-world evidence of venetoclax vs ibrutinib vs idelalisibПодробнее

Current research into drug treatments for CLL - specifically ibrutinib, idelalisib and venetoclaxПодробнее

How to manage infections in CLL patients on idelalisibПодробнее

Unmet need: CLL patients intolerant to novel therapiesПодробнее

iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucilПодробнее

Copanlisib for People with MCL Previously Treated with IbrutinibПодробнее

CLL: Chemotherapy and Ibrutinib based regimensПодробнее